Trypanosomiasis: Clinical Trials

14 trials for Trypanosomiasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed. 14 Phase 2, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 214Completed 14
Phase 36Completed 6

Follow Trypanosomiasis: new trials by email Literature Review of Trypanosomiasis trials Research Report on Trypanosomiasis

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
Acoziborole - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection
Phase 2 / Phase 3CompletedDrugs for Neglected Diseases352022-07-092026-04-06
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
Acoziborole, Placebo - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection
Phase 2 / Phase 3CompletedDrugs for Neglected Diseases12082021-12-302025-03-20
New Therapies and Biomarkers for Chagas Infection
Benznidazole, Nifurtimox - Trypanosoma Cruzi Infection, Chagas Disease
Phase 2CompletedUniversity of Texas, El Paso4502019-12-182024-07-17
Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense
Fexinidazole - Trypanosomiasis, African, Sleeping Sickness
Phase 2 / Phase 3CompletedDrugs for Neglected Diseases452019-09-292025-01-30
Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease
Fexinidazole, Placebo Oral Tablet - Chagas' Disease (Chronic) Nos
Phase 2CompletedDrugs for Neglected Diseases452017-11-132020-09-23
Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.
Benznidazole - Chagas Disease, Trypanosoma Cruzi Infection
Phase 2CompletedHospital Universitari Vall d'Hebron Research Institute2382017-04-212023-12-19
Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
Acoziborole - Trypanosomiasis, African, Gambiense Trypanosomiasis
Phase 2 / Phase 3CompletedDrugs for Neglected Diseases2082016-10-112025-09-17
Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy
Treatment with G-CSF (Granulocyte colony stimulating factor), Placebo saline - Chronic Chagasic Myocarditis
Phase 2CompletedHospital Sao Rafael702015-09-012020-08-24
Cardiac Rehabilitation in Chagas Heart Failure
Exercise, nutritional and pharmaceutical counseling - Chagas Disease, Chagas Cardiomyopathy
Phase 2 / Phase 3CompletedEvandro Chagas National Institute of Infectious Disease122013-05-012015-08-05
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
Fexinidazole, Nifurtimox, Eflornithine - Human African Trypanosomiasis (HAT), Sleeping Sickness
Phase 2 / Phase 3CompletedDrugs for Neglected Diseases3942012-10-012018-02-20
A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
Posaconazole, Placebo for posaconazole, Benznidazole - Chagas Disease
Phase 2CompletedMerck Sharp & Dohme LLC1202011-07-062018-08-27
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
Benznidazole, Posaconazole - Chagas Disease
Phase 2CompletedHospital Universitari Vall d'Hebron Research Institute782010-09-012013-09-10
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
DB289, Pentamidine - African Trypanosomiasis
Phase 2CompletedImmtech Pharmaceuticals, Inc1112003-02-012008-12-08
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
DB289 - Trypanosomiasis, African
Phase 2CompletedImmtech Pharmaceuticals, Inc302001-08-012008-12-05

Narrower conditions

Chagas Disease (7)  ·  Trypanosomiasis, African (7)  ·  Infections (3)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Chagas Cardiomyopathy (1)  ·  Neglected Diseases (1)  ·  Parasitic Diseases (1)  ·  Pyloric Stenosis, Hypertrophic (1)

Broader conditions

Euglenozoa Infections (14)  ·  Protozoan Infections (14)  ·  Vector Borne Diseases (14)  ·  Parasitic Diseases (13)  ·  Infections (11)  ·  Bronchial Diseases (1)  ·  Bronchiolitis (1)  ·  Bronchiolitis Obliterans (1)  ·  Bronchitis (1)  ·  Cardiomyopathies (1)  ·  Cardiovascular Diseases (1)  ·  Digestive System Diseases (1)  ·  Disease Attributes (1)  ·  Gastric Outlet Obstruction (1)

Interventions

benzonidazole (4)  ·  fexinidazole (3)  ·  Nifurtimox (2)  ·  posaconazole (2)  ·  Eflornithine (1)  ·  Exercise (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Pentamidine (1)  ·  SCYX 7158 (1)  ·  Sodium Chloride (1)  ·  Therapeutics (1)

Sponsors

Drugs for Neglected Diseases (6)  ·  Hospital Universitari Vall d'Hebron Research Institute (2)  ·  Immtech Pharmaceuticals, Inc (2)  ·  Evandro Chagas National Institute of Infectious Disease (1)  ·  Hospital Sao Rafael (1)  ·  Merck Sharp & Dohme LLC (1)  ·  University of Texas, El Paso (1)

Countries

Democratic Republic of the Congo (4)  ·  Brazil (3)  ·  Guinea (3)  ·  Republic of the Congo (3)  ·  Spain (3)  ·  Angola (1)  ·  Argentina (1)  ·  Bolivia (1)  ·  Central African Republic (1)  ·  Colombia (1)  ·  Malawi (1)  ·  Uganda (1)

Top investigators

Andrea S Sousa, PhD (1)  ·  Bruno SF Souza, MD, Msc (1)  ·  Carolina T Macedo, MD, Msc (1)  ·  Christian Burri, MSc, PhD (1)  ·  Clarissa LM Souza, MD (1)  ·  Enock Matovu, Prof (1)  ·  Faustino Torrico, M.D., Ph.D (1)  ·  Gomez Jordi, MD (1)  ·  Igor C Almeida, D.Sc. (1)  ·  Israel Molina, PhD (1)  ·  Joaquim Gascon, M.D., Ph.D (1)  ·  Milena BP Soares, PhD (1)

Results publications

PMID 26881924, PMID 24827034, PMID 28231946, PMID 29113731, PMID 32293523, PMID 34972765, PMID 35757326, PMID 36460027, PMID 38218194, PMID 38218195, PMID 40288400, PMID 42772313

NIH funding

2016 (2), U01AI129783 (1)